<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024400</url>
  </required_header>
  <id_info>
    <org_study_id>C09-33</org_study_id>
    <secondary_id>2009-016660-36</secondary_id>
    <nct_id>NCT01024400</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women</brief_title>
  <acronym>PREFLUVAC</acronym>
  <official_title>Etude de Phase II évaluant l'immunogénicité et la tolérance d'un Vaccin inactivé Non adjuvanté Contre la Grippe A(H1N1)v Chez la Femme Enceinte</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and safety of an inactivated, non
      adjuvanted A(H1N1)v influenza vaccine in 120 pregnant women.

      Study procedures will include 2 doses of vaccine, blood samples, cord blood samples at
      delivery and recording temperature and vaccine side effects in a memory aid for 7 days
      following each vaccination. Participants will be involved in study related procedures about 3
      at 5 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity: proportion of subjects achieving a serum HAI antibody titer of greater than or equal to 1:40, proportion of subjects with 4-fold or greater HAI antibody titer increases against H1N1 2009 virus following H1N1 vaccine.</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: occurence of local and systemic adverse events</measure>
    <time_frame>Throughout the course of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: proportion of subjects achieving a serum HAI antibody titer of greater than or equal to 1:40, proportion of subjects with 4-fold or greater HAI antibody titer increases against H1N1 2009 virus following H1N1 vaccine.</measure>
    <time_frame>Day 42 and at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety:occurence of vaccine-associated serious adverse events</measure>
    <time_frame>Throughout the course of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-adjuvanted A(H1N1)v influenza vaccine</intervention_name>
    <description>15 mcg HA/0.5 ml</description>
    <arm_group_label>vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years to 45 years

          -  Pregnancy between 22 and 32 weeks of gestation

          -  Provides written informed consent

          -  Covered by French Social Security

        Exclusion Criteria:

          -  Allergy to eggs or other components in the vaccine

          -  History of severe reactions following previous influenza vaccines

          -  H1N1 influenza (virologically documented) during the last 6 months

          -  Febrile episode within one week prior to vaccination

          -  Known HIV, HBV, HCV infection

          -  Multiple sclerosis

          -  History of Guillain-Barré syndrome

          -  Organ transplant recipient

          -  Neoplastic disease in the past 3 years

          -  Other vaccine within 3 weeks prior to study entry or planned within the month
             following the last injection

          -  Systemic corticosteroids,immunotherapy,chemotherapy

          -  Anticoagulant treatment

          -  Immunoglobulin or blood transfusion within the 3 months prior to enrollment in this
             study

          -  History of cardiac disease

          -  Chronic liver disease

          -  Diabetes before pregnancy

          -  History of premature delivery

          -  History of eclampsia

          -  Fetal morphologic abnormalities
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Odile Launay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe hospitalier Cochin Saint Vincent de Paul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vassilis Tsatsaris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe hospitalier Cochin Saint Vincent de Paul</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Besançon-Hôpital Saint-Jacques</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier Cochin Saint Vincent de Paul</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75935</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sud de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>December 29, 2011</last_update_submitted>
  <last_update_submitted_qc>December 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

